Table 1 Demographic data of enrolled patients.

From: Randomized controlled trial of early endoscopy for upper gastrointestinal bleeding in acute coronary syndrome patients

 

Non-EE group (n = 21)

EE group (n = 22)

p-value

Age (years, mean ± SD)

70.67 ± 12.82

63.55 ± 12.19

0.069

Gender, female/male, n (%)

8 (38.10)/13 (61.90)

4 (18.18)/18 (81.82)

0.146

BMI (kg/m2, mean ± SD)

23.71 ± 3.21

24.29 ± 3.38

0.573

Cigarette smoking, n (%)

8 (38.10)

13 (59.10)

0.169

Prior CAD history, n (%)

9 (42.86)

9 (40.91)

0.897

PUD history, n (%)

4 (19.05)

6 (27.27)

0.523

Drug history, n (%)

Prophylactic PPI

13 (61.9)

15 (68.2)

0.666

Aspirin alone

1 (4.76)

2 (9.09)

0.578

Clopidogrel alone

3 (14.29)

4 (18.18)

0.729

Dual antiplatelet

17 (80.95)

16 (72.73)

0.523

NSAIDs

3 (14.29)

2 (9.09)

0.595

MAP (mmHg)

86.44 ± 15.01

84.40 ± 18.77

0.698

UGIB presentation, n (%)

Tarry stool

15 (71.43)

18 (81.82)

0.420

Hematemesis

2 (9.52)

2 (9.09)

0.961

Coffee ground emesis

9 (42.86)

8 (36.36)

0.663

UGIB severity (mean ± SD)

Rockall score

4.14 ± 1.35

5.55 ± 2.70

0.039

Blatchford score

11.14 ± 5.19

11.91 ± 4.47

0.606

APACHE-II

13.24 ± 8.56

17.23 ± 13.50

0.256

Timing of UGIB after onset of ACS (hours, mean ± SD) (range)

45.93 ± 62.26 (3–202)

83.74 ± 96.61 (3–410)

0.137

Timing of endoscopy after UGIB (hours, mean ± SD) (range)

NA

13.56 ± 6.95 (2.23–22.68)

NA

Laboratory before intervention

BUN/CRE (mg/dL, mean ± SD)

39.19 ± 22.69/1.35 ± 2.43

37.91 ± 31.49/0.99 ± 0.29

0.880/0.483

BUN/CRE ratio > 20, n (%)

14 (66.7)

15 (68.2)

0.916

CCr (mL/min, mean ± SD)

69.60 ± 23.70

78.55 ± 32.24

0.308

Hb (g/dL)

9.29 ± 2.68

9.23 ± 3.04

0.943

Platelet count (k/mm3)

220.52 ± 70.20

236.18 ± 106.15

0.358

PTINR/aPTT (second)

1.06 ± 0.16/33.56 ± 16.47

1.08 ± 0.12/35.76 ± 26.75

0.554/0.748

Cardiac function (mean ± SD)

CK-MB (ng/mL)

230.15 ± 348.62

225.52 ± 272.95

0.962

Killip score I and II/III and IV, n (%)

10 (47.62)/11 (52.38)

11 (50.00)/11 (50.00)

0.880

TIMI score

6.52 ± 2.84

5.77 ± 2.52

0.364

Multi-vessel disease, n (%)

19 (90.48)

16 (72.73)

0.135

Management of ACS

Medical therapy alone for ACS, n (%)

1 (4.76)

1 (4.55)

 

Coronary artery catheterization, n (%)

20 (95.24)

21 (95.45)

0.973

 POBA

0 (0.00)

1 (4.76)

0.323

 POBAS

16 (80.00)

15 (71.43)

0.558

 Without intervention

4 (20.00)

5 (23.81)

0.768

Discontinuation of antiplatelet, n (%)

Aspirin hold

16 (76.19)

15 (68.18)

0.558

Clopidogrel hold

8 (38.10)

9 (40.91)

0.850

All

7 (33.33)

8 (36.36)

0.840

Resuming any antiplatelet agent after intervention, (days, mean ± SD)

8.63 ± 5.26

5.13 ± 1.89

0.098

Follow-up period (years, mean ± SD)

2.52 ± 2.11

2.83 ± 2.44

0.665

  1. APACHE-II Acute Physiology and Chronic Health Evaluation-II, aPTT activated partial thromboplastin time, BMI body mass index, BUN blood urea nitrogen, CAD coronary artery disease, CCr creatinine clearance rate, CRE creatinine, Hb hemoglobin, EE early endoscopy, MAP mean arterial pressure, NSAID non-steroid anti-inflammatory drug, POBA percutaneous old balloon angioplasty, POBAS percutaneous old balloon angioplasty with stent, PPI proton pump inhibitor, PTINR prothrombin time international normalized ratio, PUD peptic ulcer disease, SD standard deviation, TIMI Thrombolysis In Myocardial Infarction, UGIB upper gastrointestinal bleeding.
Back to article page